BioInsights - Viral vector bioprocessing & analytics: tools and innovations to meet future demand - spotlight

CELL & GENE THERAPY INSIGHTS

Viral vector bioprocessing & analytics: tools and innovations to meet future demand

Nolan Sutherland

Guest Editor:

Nolan Sutherland, Scientist, Molecular and Vector Biology at bluebird bio

April 2020

Download full spotlight

AAV downstream processing for industrial scale production – moving towards commercial manufacturing

Orjana Terova, Senior Product Manager, POROS Chromatography Product Line at Thermo Fisher Scientific

Mikhail Goldfarb, Principal Scientist, Downstream Process Development at Regenxbio, Inc

20 May 2020

Webinar

Watch now
Scaling AAV vector manufacture: overcoming roadblocks to the translation of gene therapies

N Faust

15 May 2020

Interview

Read more
What is ‘quality’ in viral vector manufacture? Strengths and limitations of current analytical tools

M Hörer

5 May 2020

Interview

Read more
Vector production in academia: obstacles and opportunities

D Bischof,

E Hopewell

5 May 2020

Interview

Read more
Drawing parallels and cross-pollinating ideas between viral vector and vaccine fields

A Kamen

5 May 2020

Interview

Read more
Lentiviral vector manufacturing process enhancement utilizing TFDF^™ technology

T Williams,

O Goodyear,

L Davies et al.

5 May 2020

Expert Insight

Read more
Stable AAV producer cell lines: elevating vector manufacturing

Silke Wissing, Chief Scientific Officer

5 May 2020

Webinar

Watch now
Development and validation of quantitative real-time PCR for the detection of residual HEK-293 host cell DNA

K Norman

29 April 2020

Innovator Insight

Read more
Advances in gene therapy delivery: next-generation transfection reagent for large-scale AAV manufacturing

Mathieu Porte, BioProduction R&D Manager, Polyplus-transfection

Malik Hellal, Senior Scientist, Chemistry at Polyplus-transfection

29 April 2020

Webinar

Watch now
A reproducible, high-throughput platform to quantitatively study AAVs

J White,

N Rodionova

28 April 2020

Innovator Insight

Read more
How are fixed-bed bioreactors set to change viral vector processing?

P Velthof,

P Puri,

J Van Vliet

28 April 2020

Interview

Read more
Are suspension-based systems for cell and gene therapy key to commercial-scale manufacture?

P

27 April 2020

Interview

Read more
Scaling up viral vector manufacturing with adherent and suspension cell cultures

Clive Glover, Director, Strategy at Pall Biotech

Rachel Legmann, Senior Cell Culture Process Development Manager at Pall Biotech

Siddharth Gupta, Senior Bioprocess Specialist at Pall Biotech

21 April 2020

Webinar

Watch now
Lentiviral vector process to accelerate cell and gene therapy clinical development and commercialization

Kevin Beck, Senior Account Manager at Lentigen Technology Inc

16 April 2020

Webinar

Watch now